Eli Lilly (LLY)

Last Price1,396.75

Change+42.75 (3.16%)

NYSE · Last Trade: Nov 9th, 11:51 AM EST

Quote News Press Releases Chart Historical FAQ About Competitors

Detailed Quote

Previous Close	1,354.00
Open	1,365.39
Bid	1,396.61
Ask	1,396.91
Day's Range	1,364.58 - 1,402.26
52 Week Range	850.51 - 1,453.00
Volume	1,045,090
Market Cap	1.34T
PE Ratio (TTM)	45.33
EPS (TTM)	30.8
Dividend & Yield	6.920 (0.50%)
1 Month Average Volume	2,857,964

Chart

About Eli Lilly (LLY)

Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More

News & Press Releases

Gabelli Releases Agenda for 8th Annual Healthcare Symposium

PALM BEACH, Florida, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Gabelli today released the agenda for its 8th Annual Healthcare Symposium to be held this Friday, November 13 in conjunction with Columbia Business School at the Paley Center for Media in New York. The symposium will bring together leading companies and organizations from across the healthcare ecosystem, with an emphasis on industry dynamics, current trends, and business fundamentals.

By Gabelli Funds · Via GlobeNewswire · November 9, 2026

Eli Lilly Is Now Worth Nearly 9 Novo Nordisks. Here's How the Gap Got So Wide.fool.com

The companies are competing in the weight loss drug market.

Via The Motley Fool · November 9, 2026

New Independent Research Hub Launches for Eloralintide, Lilly’s Investigational Amylin Agonist

Eloralintide-Peptide.com brings Phase 2 and Phase 3 trial data, comparisons with semaglutide, tirzepatide, retatrutide and cagrilintide, and sourcing checks together in one place

Via Press Release Distribution Service · November 9, 2026

3 Super Growth Stocks to Buy Hand Over Fist If the Stock Market Crashesfool.com

One of these stocks is up 265% over the past year -- and its shares don't seem wildly overvalued, either.

Via The Motley Fool · November 8, 2026

Novo Nordisk's Wegovy Pill Has Topped 5 Million Prescriptions. Is the Stock a Buy Now?fool.com

Novo Nordisk is looking to build a volume-driven business, but the successful launch of the Wegovy pill is just the first step.

Via The Motley Fool · November 8, 2026

Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trialsfool.com

Everyone is talking about the GLP-1 battle between Eli Lilly and Novo Nordisk, but Pfizer wants in on the fight, too.

Via The Motley Fool · November 7, 2026

Eli Lilly Just Raised Its 2026 Revenue Forecast by $5.5 Billion. Is the Stock Still a Buy?fool.com

The stock is expensive, but the potential market for GLP-1 drugs is likely much larger than forecast.

Via The Motley Fool · November 7, 2026

IYH and XBI: Two Distinct Paths to Investing in Healthcarefool.com

XBI delivered stronger 1-year returns at 45%, but IYH's diversified portfolio weathered volatility far better, with a maximum drawdown of just 17.9% versus 53.2%.

Via The Motley Fool · November 7, 2026

Certified PEP MEX Expands Its Reach in Mexico With Two New Research Peptide Websites

Péptidos Verificados brings the full catalog together for online purchase, while Péptido Retatrutida focuses on a molecule as it rounds out its Phase 3 program.

Via Press Release Distribution Service · November 7, 2026

Eli Lilly Is Much More Than a Weight-Loss Drug Company. Here's the Evidencefool.com

Eli Lilly could thrive even as competition in the weight-loss market intensifies.

Via The Motley Fool · November 6, 2026

Hims & Hers Surges On 'Surprising And Inevitable' Deal With Eli Lillyinvestors.com

Hims & Hers Health inked a deal with Eli Lilly on Friday to sell the company's obesity drugs.

Via Investor's Business Daily · November 6, 2026

Lilly and Hims & Hers expand access to FDA-approved Lilly medicines

Eli Lilly and Company (NYSE: LLY) and Hims & Hers Health, Inc. (NYSE: HIMS) today announced an agreement to help expand access to Zepbound (tirzepatide) and Foundayo (orforglipron). Through the agreement, eligible patients who receive a prescription from a licensed provider on the Hims & Hers platform will access the same self-pay prices available to any patient without leaving the Hims & Hers platform.

By Hims & Hers · Via Business Wire · November 6, 2026

2 Growth Stocks to Buy in November Without Any Hesitationfool.com

They have both outperformed the broader equity market over the long run.

Via The Motley Fool · November 5, 2026

Here's the 1 Stock I'd Most Want to Buy If the Market Crashesfool.com

Investors should look to defensive stocks in the healthcare sector during a major market correction.

Via The Motley Fool · November 5, 2026

OPKO Health (OPK) Q3 2026 Earnings Call Transcriptfool.com

Sale of BioReference brings $722 million in cash as the company narrows its focus to biotech.

Via The Motley Fool · November 5, 2026

These 6 Stocks Make Up a Big Share of the S&P 500fool.com

Six tech stocks make up nearly a third of the S&P 500. Here's how AI spending is shaping each one's results.

Via The Motley Fool · November 5, 2026

Elanco (ELAN) reports earnings tomorrow: what to expect

Animal health company Elanco (NYSE:ELAN) will be reporting results this Friday before market hours. Here’s what to expect. Elanco beat analysts’ revenue expe...

Via StockStory · November 4, 2026

The Nasdaq-100 Is Outperforming Nvidia, Microsoft, Amazon, Meta Platforms, Alphabet, and Tesla This Year. Here's My Favorite Low-Cost ETF to Buy the Dip.fool.com

Many megacap growth stocks are underperforming the major indexes this year.

Via The Motley Fool · November 4, 2026

If the S&P 500 Falls 20%, Here's the 1 ETF I'd Buy Hand Over Fistfool.com

Some individual stocks keep falling. The broader U.S. stock market has always bounced back.

Via The Motley Fool · November 4, 2026

Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors.fool.com

Viking aims to enter the weight loss drug market.

Via The Motley Fool · November 4, 2026

What to expect from ANI Pharmaceuticals’s (ANIP) Q3 earnings

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be reporting earnings this Thursday before market open. Here’s what investors should ...